Product Data Sheet

Product Name: UNC7467
Cat. No.: GC67791

Chemical Properties

Cas. No.

Formula	$C_{20}H_{13}NO_3$	M.Wt	315.32
Solubility	DMSO : 14.29 mg/mL (45.32 mM; ultrasonic and warming and heat to 60°C)	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	UNC7467		

Background

UNC7467 is a potent **IP6K** inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research[1].

UNC7467 (2.5 μM; 3 hours; HCT116 cells) reduces levels of inositol pyrophosphates. UNC7467 reduces 5-InsP$_7$ levels by 81% and 5-InsP$_8$ levels by 63%[1].

UNC7467 (5 mg/kg; i.p.; daily, for 4 weeks; diet-induced obesity mice) ameliorated diet induced obesity, insulin resistance, and hepatic steatosis[1].
UNC7467 (1-5 mg/kg; i.v. and i.p.; diet-induced obesity mice) exhibits low clearance (13.7 (mL/min)/kg) and large AUC_{last} (6054 h•ng/mL for intra venous (i.v.) and 2527 h•ng/mL for intraperitoneal (i.p.)) in mice at 5 mg/kg dose[1].

Animal Model: Diet-induced obesity (DIO) mice[1]

Dosage: 5 mg/kg

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Administration:	Intraperitoneal injection; daily, for 4 weeks
Result:	Improved glycemic profiles, ameliorated hepatic steatosis, and reduced weight gain without altering food intake.
Animal Model:	Diet-induced obesity (DIO) mice[1]
Dosage:	5 mg/kg (Pharmacokinetic Analysis)
Administration:	Intravenous injection and intraperitoneal injection

Result:

route	iv	ip
Dose (mg/kg)	5	5
AUC_{last} (h*ng/mL)	6054	2527
CL (mL/min/kg)	13.7	

[1]. Zhou Y, et, al. Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions. J Med Chem. 2022 May 12;65(9):6869-6887.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA